( DrugBank: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
230 | 肺胞低換気症候群 | 8 |
230. 肺胞低換気症候群
臨床試験数 : 8 / 薬物数 : 11 - (DrugBank : 5) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 28
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04108819 (ClinicalTrials.gov) | October 30, 2019 | 26/9/2019 | Ketogenic Diet for Obesity Hypoventilation Syndrome | Ketogenic Diet for Obesity Hypoventilation Syndrome | Obesity Hypoventilation Syndrome;Ketogenic Dieting;Hypercapnic Respiratory Failure | Dietary Supplement: Ketogenic Diet | Johns Hopkins University | NULL | Recruiting | 18 Years | 75 Years | All | 25 | N/A | United States |
2 | NCT01964339 (ClinicalTrials.gov) | October 9, 2013 | 14/10/2013 | Obesity Hypoventilation Syndrome Prevalence Study | Obesity Hypoventilation Syndrome Prevalence Study | Obesity Hypoventilation Syndrome | Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.;Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study. | Philips Respironics | NULL | Terminated | 21 Years | N/A | All | 44 | United States | |
3 | NCT01500473 (ClinicalTrials.gov) | February 2012 | 22/12/2011 | Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome | Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome | Congenital Central Hypoventilation Syndrome | Drug: Desogestrel | Children's Hospital Los Angeles | NULL | Not yet recruiting | 16 Years | 50 Years | Female | 8 | N/A | United States |
4 | NCT01499485 (ClinicalTrials.gov) | November 2011 | 20/12/2011 | Treatment of Metabolic Alkalosis With Acetazolamide. Effect on the Length of Mechanical Ventilation. | Effects of Acetazolamide on the Duration of Mechanical Ventilation in Patients With Metabolic Alkalosis. Phase III Multicenter Double-blinded Clinical Trial. | Pulmonary Disease, Chronic Obstructive;Obesity Hypoventilation Syndrome;Metabolic Alkalosis | Drug: Acetazolamide;Drug: Placebo | Hospital Son Llatzer | NULL | Completed | 18 Years | N/A | Both | 140 | Phase 3 | Spain |
5 | NCT01243697 (ClinicalTrials.gov) | April 2011 | 17/11/2010 | Assessment of Desogestrel in Ondine Syndrome | Assessment of Desogestrel for a Pharmacological Recovery of Ventilatory Activity in Congenital Central Hypoventilation Syndrome - Ondine Syndrome | Ondine Syndrome | Drug: desogestrel | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 10 Years | 60 Years | Female | 6 | Phase 2/Phase 3 | France |
6 | ChiCTR-DDT-11001215 | 2010-07-01 | 2011-03-05 | Double position CT investigation of OSAHS | Double position CT investigation of OSAHS | Obstructive sleep apnea hypoventilation syndrome | Gold Standard:;Index test:; | First Hospital of Peking university | NULL | Completed | Both | Target condition:0;Difficult condition:0 | China | |||
7 | EUCTR2005-005950-33-SE (EUCTR) | 07/06/2006 | 10/04/2006 | Studie av Domperidon och barn med kongenitalt centralt hypoventilationssyndrom. - DOMPCCHSSWE1 | Studie av Domperidon och barn med kongenitalt centralt hypoventilationssyndrom. - DOMPCCHSSWE1 | Congenital central hypoventilation syndrome, CCHS or Ondine's curse. | Trade Name: Motilium<br>Product Name: Motilium<br>INN or Proposed INN: Domperidone | Karolinska Universitetssjukhuset | NULL | Authorised-recruitment may be ongoing or finished | <an>br>Female: yes Male: yes | Sweden | ||||
8 | EUCTR2011-000989-35-FR (EUCTR) | 06/05/2011 | N/A | N/A - RESPIRONDINE | MedDRA version: 14.0;Level: PT;Classification code 10066131;Term: Congenital central hypoventilation syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders | Trade Name: Cerazette<br>Product Name: Cerazette<br>INN or Proposed INN: Désogestrel | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | NA | <pan>br>Female: yes Male: no | Phase 2 | France |